Pharmaceutical titan AstraZeneca dropped after reporting that full-year revenue fell 15 per cent due to a loss of exclusivity on several brands. The company also said that it would not buy back any shares in 2013 "in order to maintain the flexibility to invest the business". [31 Jan '13]
Panmure Gordon has kept its 'hold' rating and 3,000p target price for pharmaceuticals giant AstraZeneca after the firm's final results, saying that figures were not as bad as they could have been. [31 Jan '13]
The man responsible for setting boardroom pay at Barclays was hammered by MPs and peers yesterday and warned not to pay a one million-pound bonus to the new chief executive. Sir John Sunderland, one of Britain's most eminent industrialists and a for- mer CBI president, was hit by a barrage of hostile questioning and accused of a significant misjudgment in approving a 2.7 million-pound bonus to Bob Diamond, the bank's former chief, last year. He was also told that the embattle [31 Jan '13]
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.